Martin Auster
Stock Analyst at Raymond James
(4.31)
# 354
Out of 5,182 analysts
54
Total ratings
60.47%
Success rate
16.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Initiates: Strong Buy | $6 | $2.05 | +192.68% | 1 | Apr 14, 2026 | |
| SYRE Spyre Therapeutics | Initiates: Strong Buy | $80 | $68.63 | +16.57% | 1 | Apr 14, 2026 | |
| EVMN Evommune | Initiates: Strong Buy | $40 | $25.58 | +56.37% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $24.28 | +56.54% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $69.71 | +1.85% | 2 | Oct 30, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $67.26 | +60.57% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $222.08 | +22.03% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $18.16 | +92.73% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $302.11 | +40.35% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $53.30 | +125.14% | 7 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $99 → $105 | $24.53 | +328.05% | 7 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $7.44 | +249.46% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $7.45 | +1,510.74% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $33.33 | +74.02% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $569.11 | -65.56% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.64 | +5,875.61% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $134.94 | -55.54% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $46.73 | +39.10% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $21.07 | +246.46% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $18.05 | +332.13% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.91 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.83 | +386.98% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $13.20 | +59.09% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $66.11 | -75.80% | 1 | May 7, 2020 |
Equillium
Apr 14, 2026
Initiates: Strong Buy
Price Target: $6
Current: $2.05
Upside: +192.68%
Spyre Therapeutics
Apr 14, 2026
Initiates: Strong Buy
Price Target: $80
Current: $68.63
Upside: +16.57%
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $25.58
Upside: +56.37%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $24.28
Upside: +56.54%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $69.71
Upside: +1.85%
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $67.26
Upside: +60.57%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $222.08
Upside: +22.03%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $18.16
Upside: +92.73%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $302.11
Upside: +40.35%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $53.30
Upside: +125.14%
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $24.53
Upside: +328.05%
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $7.44
Upside: +249.46%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $7.45
Upside: +1,510.74%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $33.33
Upside: +74.02%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $569.11
Upside: -65.56%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.64
Upside: +5,875.61%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $134.94
Upside: -55.54%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $46.73
Upside: +39.10%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $21.07
Upside: +246.46%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $18.05
Upside: +332.13%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $1.91
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.83
Upside: +386.98%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $13.20
Upside: +59.09%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $66.11
Upside: -75.80%